Credits: Canva
Do you know who can donate blood to you or who can you donate blood to? Blood donation may not be complex, but it does need to be compatible with yours and vice-versa. The blood types are determined by the presence or absence of certain antigens - substance that can trigger immune response if they are foreign to the body.
There are four major blood groups which are determined by the presence or absence of two antigens, A and B, on the surface of red blood cells. There is also a protein called the Rh factor, which can either be present (+) or absent (-), which creates A+, A-, B+, B-, O+. O-, AB+, AB- blood types.
Group A blood type has only A antigens on red blood cells and B antibody in the plasma. B has only B antigen on red cells and A antibody in the plasma. AB has both A and antigens on red cells, but neither A nor B antibody is present in the plasma. O has neither A nor B antigens on red cells, but both A and B antibody are present in the plasma.
Your blood type determines who can you donate to. This is because there are very specific ways in which blood types must be matched for safe transfusion. The right blood transfusion could actually save you, while the wrong one could be lethal. Also, Rh-negative blood is given to Rh-negative patients and Rh-positive or Rh-negative blood can only be given to Rh-positive patients.
If you are O blood type, you can donate to O, A, B, and AB, if you are A blood type, you can donate to A and AB, if you are B blood type, you can donate to B and AB, however if you are AB, you can only donate to AB.
If you are O blood type, you can only receive from O. If you are A, you can receive from type A and O. If you are blood type B, you can receive from type B and O. If you are AB, you are lucky, you can receive blood from O, A, B, and AB.
There are more than 600 other known antigens, the presence or absence of which creates "rare blood types". Certain types are unique to specific ethnic or racial groups, this is why an African-American blood donation can be the best hope for the needs of patients with sickle cell disease, as per the Red Cross Organization.
Type O is one in high demand, as it can donate blood to anyone. O negative blood type is the universal blood type, which can donate to everyone, especially during the emergency transfusions and for immune deficient infants.
In the US, 37% Caucasian, 47% African-American, 39% Asians, and 53% Latino-American are O-positive. However, only 8% of Caucasian, 4% of African-American, 1% Asian, and 4% Latino=Americans are O-negative.
A+: 33% Caucasian, 34% African-American, 27% Asian, 29% Latino-American
A-: 7% Caucasian, 2% African-American, .5% Asian, 2% Latino-American
B+: 9% Caucasian, 18% African-American, 25% Asian, 9% Latino-American
B-: 2% Caucasian, 2% African-American, .4% Asian, 1% Latino-American
AB+:3% Caucasian, 4% African-American, 7% Asian, 2% Latino-American
AB-: 1% Caucasian, .3% African-American, .1% Asian, .2% Latino-American
Credit: iStock
India, which carries the world's second-largest population of hemophilia cases—a genetic blood disorder—must shift towards prophylaxis care for the bleeding disorder, said health experts today on the occasion of World Hemophilia Day.
World Hemophilia Day is observed every year on April 17 to raise global awareness of hemophilia and other inherited bleeding disorders.
This year’s theme of “Diagnosis: First step to care” highlights the critical importance of diagnosis—the essential first step in treatment and care.
According to the World Federation of Hemophilia (WFH), 75 percent of people suffer from hemophilia, without even knowing it, simply because they don’t have access to basic healthcare.
Hemophilia is a rare bleeding disorder where blood does not clot properly, even for minor injuries. It is caused by an error in a specific gene on the X chromosome, leading to a deficiency or absence of clotting factors.
While the condition mainly affects males, women are the genetic carriers. In people with hemophilia, the blood lacks sufficient clotting factors -- which are proteins essential for stopping bleeding.
Whether the bleeding is external, such as cuts, or internal, such as bleeding into joints or muscles, the blood does not clot. So, it can be a very serious disorder.
Without consistent care, repeated bleeding into joints can lead to
Hemophilia is mainly of three types:
Hemophilia A, the most common type, affects about 1 in 5,000 male births, underscoring the urgent need for improved detection and awareness.
Hemophilia B, on the other hand, is an X-linked genetic disorder affecting 1 in approximately 25,000 male births.
India bears a significant burden from Hemophilia A. Estimates suggest around 136,000 individuals are affected, but only a small fraction are diagnosed and registered due to unequal access to essential care.
Dr. Varun Kaul, Professor, Dept of Pediatrics, Guru Gobind Singh Medical College & Hospital, Faridkot, told HealthandMe that in India, systemic gaps, ranging from limited diagnostic access to unevenly distributed treatment centers, continue to restrict access to RRT, especially beyond metro cities.
In contrast, more than 50 per cent of persons with hemophilia globally benefit from regular replacement therapy (RRT) as the standard of care.
Routine replacement therapy (RRT), commonly known as prophylactic care or prophylaxis, is the standard treatment for severe hemophilia.
It involves the regular intravenous (IV) infusion of clotting factor concentrates to maintain factor levels above 1 per cent to prevent spontaneous bleeding, particularly into joints and muscles.
Most Indian patients currently rely on reactive, on-demand therapy to manage bleeds after they happen.
Dr. Kaul said that although this may help prevent the immediate crisis, it fails to stop the cumulative joint damage that often results in permanent disability.
“Providing regular, scheduled infusions to maintain sufficient clotting factor levels can prevent bleeds entirely, reducing annual bleed rates by 90 per cent and enabling a life free from chronic pain and constant fear of the next bleed,” Dr. Kaul said.
Some progress is visible, as States like Karnataka, Kerala, Jammu and Kashmir, to name a few, have pioneered state-sponsored RRT programs.
“It is now imperative to transition from mere crisis management toward implementing preventive care as a National Health priority,” Dr Kaul added.
Dr Rahul Bhargava, Principal Director & Chief - Hematology, Hemato-Oncology & Bone Marrow Transplant, Fortis Memorial Research Institute, Gurugram, stressed the importance of focusing the treatment on females.
"Carrier testing in hemophilia remains largely focused on affected males, while women who may be carriers are often not included in routine screening,” Dr Bhargava told HealthandMe.
As an X-linked inherited disorder, hemophilia can present in women with low clotting factor levels, leading to
Most of the cases remain undiagnosed until a clinical event occurs.
"Identifying carriers through timely testing enables appropriate counselling and informed reproductive decisions. It also supports early diagnosis in families and reduces the risk of severe bleeding complications in future generations,” the doctor said.
Dr Tulika Seth, Professor of Haematology at All India Institute of Medical Sciences (AIIMS) in New Delhi, in a post on social media platform X, stressed the importance of testing for hemophilia.
"If a child gets prolonged bleeding from a minor cut or injury, or if there are spontaneous painful swellings in the joints after minor falls, or sometimes even by somebody holding the baby, or there's a lot of bruising, people should get the baby tested or the adult tested for hemophilia," Dr. Seth said.
She noted that in mild cases of hemophilia, sometimes a person may not be aware that they have a deficiency, and then when they go for a tooth extraction or any surgery, they may have a problem.
"So, it's important to know your family history, and if you've had any prolonged bleeding after any pain, then you should tell your doctor and get tested," the doctor said.
Dr Bhargava also called for a broader approach that includes women in screening programs to help strengthen prevention and long-term management of hemophilia across families.
Hemophilia management requires attention beyond hospital care to prevent long-term complications.
To reduce bleeding episodes, it is important to:
Other measures include
"Integrating medical treatment with lifestyle practices supports functional independence and improves overall disease control,” Dr. Bhargava told HealthandMe.
Credit: Canva
Hemophilia is a rare genetic bleeding disorder, usually inherited, wherein blood cannot clot properly due to low levels of clotting factors, causing prolonged bleeding or spontaneous internal hemorrhages.
Symptoms include easy bruising, joint pain/swelling, and excessive bleeding. While not curable, it is treated with factor replacement therapy and gene therapy.
India has the world's second-largest population of hemophilia patients, with estimates suggesting over 70,000 to over 1,36,000 cases of Hemophilia A and B. However, while around 13,000 to 19,000+ patients are registered, many remain undiagnosed.
This World Hemophilia Day, Dr. Sheikh Bilal, Head of Department, Pathology, Government Medical College, Srinagar, Kashmir, exclusively told Healthandme that the primary reason why thousands of Indians remain undiagnosed and unable to access proper care is due to budget constraints, lack of awareness among policymakers, and the need for technocrats to advocate boldly for regular replacement therapy.
Despite having the second-largest hemophilia population, only 9-10 percent receive treatment as compared to 80-100 percent in some European countries.
The expert explained: "Money plays an important role. Every center in India has, at their own level, their own policymakers and the people who are at the helm of affairs. We are the second home for the hemophilia and we can change the lives of these people by having the regular replacement but it is all depending upon the perception of individual centers."
He also noted that the government needed to introduce policy reforms endorsing regular replacement therapy as the gold standard to help ensure equitable access to patients.
The median age at diagnosis for severe hemophilia in India stands at 60 months—five full years—compared to under 12 months in high-income countries. This delay is not just a matter of time but one that poses a risk of serious clinical consequences. Late diagnosis often means repeated, unmanaged bleeding episodes during early childhood, particularly into joints, before appropriate treatment begins.
The three types of this condition include :
The treatments for haemophilia have never been more effective, but they work only for patients who have been diagnosed. In a condition where every missed bleed moves a joint closer to permanent damage, the most important clinical act is also the most basic one: recognition.
The main treatment for severe hemophilia involves replacing the clotting factor you need through a tube in a vein. This replacement therapy can be given to treat a bleeding episode in progress. It can also be given on a regular schedule at home to help prevent bleeding episodes. Some people receive continuous replacement therapy.
Replacement clotting factor can be made from donated blood. Similar products, called recombinant clotting factors, are made in a laboratory, not from human blood.
Visceral fat is one of the contributors of lean fatty liver. (Photo credit: iStock)
For many people, a normal weight brings a sense of reassurance. If the weighing scale looks fine, health is assumed to be in check. However, in clinical practice, we are increasingly seeing individuals who are not overweight yet show clear signs of fatty liver. This condition, often called lean fatty liver, is quietly becoming more common in India and is a major public health concern.
Dr Harshavardhan Rao B, HOD & Consultant, Department of Gastroenterology, Ramaiah Memorial Hospital, while talking about the possibility of people suffering from a lean fatty liver, despite normal body weight, answered all FAQs regarding the condition.
When fat accumulates in the liver of individuals who have a normal body mass index (BMI), it is referred to as "lean fatty liver." It falls under the broader category of metabolic dysfunction-associated steatotic liver disease (MASLD), but it occurs in people who do not fit the prototypical profile of being overweight with high sugar levels and uncontrolled blood pressure. It is also more common in younger age groups compared to the typical MASLD patient. This contradicts the general belief that a normal body weight and BMI are indicators of good metabolic health and, by extension, optimal liver function.
Metabolic diseases are presenting differently in the Indian population. Even individuals who appear lean may carry underlying metabolic risk. Several patterns are worth noting:
Lean fatty liver produces no obvious symptoms in the early stages. Most individuals feel entirely well. The diagnosis is typically incidental—picked up during routine health check-ups when liver enzymes are mildly elevated or when an ultrasound shows fatty changes.
The absence of warning signs has two potentially serious downstream effects. Firstly, most cases are diagnosed at a later stage when liver damage has already set in, and secondly, it makes it easy to defer action since the patient perceives no discomfort and does not feel the need to prioritise this over routine work and personal stresses.
Body weight does not give the full picture of metabolic health. A normal BMI can coexist with:
This forms the basis for the clinical category of “metabolically unhealthy, normal weight."
Beyond the standard risk factors, several contributors tend to be underappreciated:
Together, these factors can have profound effects on metabolic health and eventually lead to fatty liver and even long-term liver damage.
What Should Be Done?
The management of lean fatty liver focuses on metabolic improvement rather than weight reduction.
© 2024 Bennett, Coleman & Company Limited